Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6020439 | Journal of Neuroimmunology | 2014 | 6 Pages |
Abstract
We investigated the effect of atacicept, a recombinant fusion protein blocking BLyS and APRIL and acting on B cells, on degeneration of retinal ganglion cells (RGCs) during experimental autoimmune encephalomyelitis (EAE). We used myelin oligodendrocyte glycoprotein in Brown Norway rats to induce a variant of EAE which involves B cells and leads to severe optic neuritis. Intraperitoneal treatment with atacicept at some of the studied dose levels (100 or 200 μg) resulted in increased apoptosis of retinal ganglion cells whereas at a tenfold lower dose or in vehicle-treated animals no such effect became apparent. Also the extent of inflammation, demyelination, and axonal loss of the optic nerve was more pronounced in rats treated with the higher atacicept dose level. The present study describes observational evidence for adverse effects of atacicept on neuronal survival during EAE.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Benedikt Kretzschmar, Katharina Hein, Zahra Moinfar, Birte Könnecke, Muriel B. Sättler, Henry Hess, Robert Weissert, Mathias Bähr,